The present invention relates to extended release liquid compositions of guaifenesin. The extended release liquid compositions are in the form of suspensions which are ready-to-use or suspensions which are reconstituted from powder. It also relates to processes for the preparation of said extended release liquid compositions.

Uses and formulations of cannabinoids, in particular of cannabidiol, are provided.

The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS).

Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.

Disclosed herein are agents that target cholesterol metabolism (e.g., synthetic nanostructures), pharmaceutical compositions, kits, or methods for treating and/or preventing viral infections. In some embodiments, the agents that target cholesterol metabolism and/or pharmaceutical compositions are delivered to the subject's respiratory system. In some embodiments, the viral infection is caused by a respiratory vims. In some embodiments, the virus is adenovirus (ADV); influenza virus, human bocavims (HBoV); human coronavirus (HCoV); human metapneumo vims (HMPV); human parainfluenza virus (HPIV); human respiratory syncytial vims (HRSV); human rhino vims (HRV); severe acute respiratory syndrome coronavirus (SARS-CoV); and Middle East Respiratory Syndrome coronavirus (MERS-CoV). In some embodiments, the virus is SARS-CoV-2.

A pharmaceutical composition comprising dabigatran etexilate, and preparation method and use thereof, and solid preparation comprising the pharmaceutical composition; the pharmaceutical composition comprises a vitamin C layer and a dabigatran etexilate layer separated by a semipermeable film layer, and the semipermeable film layer comprises a water-soluble compound, a water-insoluble compound and an optional anti-sticking agent and/or plasticizer.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising at least one organic acid; at least one drug layer comprising trihexyphenidyl or a pharmaceutically acceptable salt thereof over the core; and a functional coat over the drug-layered core. The compositions of the disclosure provide extended release with reduced C.sub.max, a C.sub.min:C.sub.max ratio of ≥0.4, Fluctuation Index of ≤1, while providing and maintaining at least a minimum therapeutically effective plasma concentration, of the trihexyphenidyl or the pharmaceutically acceptable salt thereof for at least about 10 hours. The compositions of the disclosure improve solubility of the trihexyphenidyl or the pharmaceutically acceptable salt thereof at a pH of greater than or equal to 5, to provide and maintain at least a minimum effective concentration of the drug at such pH.

Methods and systems and related devices particles and compositions are described for controlled ballistic delivery of particles to a target region of a multilayered tissue, the method comprising determining a velocity v.sub.o,j of the set of substantially spherical particles by iterating v.sub.o,i=√{square root over (Y.sub.a/ρ.sub.p)}((1/k)(d*/D.sup.m)(μ.sub.a.sup.m-1)(√{square root over (Y.sub.aρ.sub.p)}).sup.1-m(ρ.sub.a/ρ.sub.p)).sup.1/n.sup.i from i=0 to j, where n.sub.0=0.826 and n.sub.i=n.sub.0−q(v.sub.0,i-1√{square root over (ρ.sub.a/Y.sub.a)}), until |(v.sub.0,i−v.sub.0,i-1)/v.sub.o,i-1|<0.1; selecting the D.sub.p, ρ.sub.p and v.sub.o,j when v.sub.o,j is less than 1,500 m/sec; and ballistically delivering a set of substantially spherical therapeutic particles having the selected D.sub.p and ρ.sub.p at velocity v.sub.o,j to the accessible surface of the apical layer of the bilayer tissue to deliver into the target region at least 30% of the set of substantially spherical particles.

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

The present invention relates to a liquisolid pharmaceutical formulation comprising a porous carrier and an active pharmaceutical ingredient loaded onto a surface of the porous carrier, wherein the active pharmaceutical ingredient is dispersed in propylene carbonate or a mixture of propylene carbonate and a further solvent and the dispersion of the active pharmaceutical ingredient and propylene carbonate or a mixture of propylene carbonate and a further solvent is loaded onto the external surface and the internal surface located inside the pores of the porous carrier thereby forming a liquisolid system, and to a process for manufacturing such a liquisolid pharmaceutical formulation.

The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.